SEC Tracker
Get the app

Verastem VSTM

Verastem reported a net loss of $74.72 million

Form
10-Q
Filed
Importance
Notable
  1. Revenue was $24.01 million for the three months ended Sep 30, 2026
  2. Diluted EPS was -$0.74 for the three months ended Sep 30, 2026
  3. Cash and equivalents were $172.8 million at Sep 30, 2026

Written from the 10-Q on EDGAR. AI can make mistakes. Check the filing.

Open in the appGet the appView on EDGAR

Get an email when Verastem files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

The reading, claim by claim

From the filing's financial data, not stated in its text

From this 10-Q's financial data (XBRL) for the quarter ended September 30, 2026

  • For the quarter ended September 30, 2026, Verastem, Inc. reported revenue of $24.0 million.
  • The company had a net income of -$74.7 million.
  • The operating margin was -313.3% and the net margin was -311.2%.
  • Revenue for the quarter increased by 113.6% compared to the same period a year earlier.
  • In its 10-Q for the quarter ended September 30, 2026, Verastem, Inc. provided financial data.
  • The filing includes revenue, income, and margin figures.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Corvus Pharmaceuticals CRVS public float $252M, Jun 30, 2025
  2. DBV Technologies DBVT public float $251M, Jun 30, 2025
  3. Atea Pharmaceuticals AVIR public float $263M, Jun 30, 2025
  4. Annexon ANNX public float $244M, Jun 30, 2025
  5. Vanda Pharmaceuticals VNDA public float $269M, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.